Nanoparticle News and Research RSS Feed - Nanoparticle News and Research

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.
Malvern launches two new ITC systems to support life science research

Malvern launches two new ITC systems to support life science research

Malvern Instruments has launched two new-generation isothermal titration calorimeters (ITC), advancing its recently acquired MicroCal range to further support life science researchers studying biomolecular interactions. The new manual Malvern MicroCal PEAQ-ITC and fully automated Malvern MicroCal PEAQ-ITC Automatedsystems are designed to deliver the enhanced functionality and robust performance now demanded of this essential tool. [More]
New medical device could revolutionise kidney disease care in the UK

New medical device could revolutionise kidney disease care in the UK

A new medical device which combines nanotechnology with a pregnancy tester could help diagnose and treat the 1 million people in the UK who don’t know they have kidney disease, a new report by the Institution of Mechanical Engineers reveals today. [More]
New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months. [More]
MIT chemical engineers develop new type of self-healing hydrogel

MIT chemical engineers develop new type of self-healing hydrogel

Scientists are interested in using gels to deliver drugs because they can be molded into specific shapes and designed to release their payload over a specified time period. However, current versions aren't always practical because must be implanted surgically. [More]
Korean scientists produce flexible, stable monolayers of protein-bound gold nanoparticles

Korean scientists produce flexible, stable monolayers of protein-bound gold nanoparticles

Free-standing nanoparticle films are of great interest for technical applications, such as the development of nanoelectronic devices. In the journal Angewandte Chemie, Korean scientists have introduced very flexible and stable monolayers of gold nanoparticles made by a self-assembly process based on protein aggregation. The films were used to coat wafers up to 10 cm in diameter. [More]
Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center. [More]
Analytical strategies that support OSD formulation: A new whitepaper from Malvern Instruments

Analytical strategies that support OSD formulation: A new whitepaper from Malvern Instruments

A new whitepaper from Malvern Instruments provides detailed guidance on the analytical technologies that help to accelerate oral solid dosage (OSD) product formulation to a successful conclusion. [More]
NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin. [More]
Magnetizing biomolecules: an interview with Dr. Fred Whipple, AMSBIO

Magnetizing biomolecules: an interview with Dr. Fred Whipple, AMSBIO

Nanoparticle technology was originally developed in the 1980s and 1990s. As the technology evolved, it soon became possible to produce uniform nanoscopic beads that are magnetic, and that also have a variety of specific surface chemistries. It was immediately evident that such beads could be used to great advantage for biochemical separations. [More]
Chili peppers show promise as diet-based supplement

Chili peppers show promise as diet-based supplement

Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits. [More]
Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist. New insights into specific gene mutations that arise in this often deadly form of brain cancer have pointed to the potential of gene therapy, but it's very difficult to effectively deliver toxic or missing genes to cancer cells in the brain. [More]
Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Research efforts associating scientists from the CNRS, UVSQ and INSERM within the Laboratoire END-ICAP, working in collaboration with a team from the University of Bern, has demonstrated the therapeutic potential of a new class of synthetic oligonucleotides in the treatment of Duchenne muscular dystrophy (DMD) using RNA "surgery". [More]
Cell-penetrating nanoparticles can efficiently transport oligonucleotide drugs into cells

Cell-penetrating nanoparticles can efficiently transport oligonucleotide drugs into cells

Therapeutic oligonucleotide analogs represent a new and promising family of drugs that act on nucleic acid targets such as RNA or DNA; however, their effectiveness has been limited due to difficulty crossing the cell membrane. [More]
Case Western researchers awarded NSF grant to develop new method to reduce risk of Ebola virus

Case Western researchers awarded NSF grant to develop new method to reduce risk of Ebola virus

Health care workers must diagnose and isolate Ebola victims at an early stage to have a chance to save them and prevent the virus from spreading. But the most sensitive and quickest diagnostic test produces a small percentage of false negative results that undermine efforts to control the deadly agent. [More]
UB researchers design nanoparticle that may open door for new 'hypermodal' imaging systems

UB researchers design nanoparticle that may open door for new 'hypermodal' imaging systems

Using two biocompatible parts, University at Buffalo researchers and their colleagues have designed a nanoparticle that can be detected by six medical imaging techniques. [More]
Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML). [More]
Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines. [More]
Exposure to nanoparticles can play major role in development of cardiovascular diseases

Exposure to nanoparticles can play major role in development of cardiovascular diseases

Nanoparticles, extremely tiny particles measured in billionths of a meter, are increasingly everywhere, and especially in biomedical products. Their toxicity has been researched in general terms, but now a team of Israeli scientists has for the first time found that exposure nanoparticles (NPs) of silicon dioxide (SiO2) can play a major role in the development of cardiovascular diseases when the NP cross tissue and cellular barriers and also find their way into the circulatory system. [More]
EnGeneIC closes oversubscribed Series B financing

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing. [More]
Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars. [More]